Literature DB >> 7569331

Fibronectin and hyaluronan in bronchoalveolar lavage fluid from young patients with chronic obstructive pulmonary diseases.

W D Song1, A C Zhang, Y Y Pang, L H Liu, J Y Zhao, S H Deng, S Y Zhang.   

Abstract

Fibronectin (FN) and hyaluronan (HA) in bronchoalveolar lavage fluid (BALF) and FN released by alveolar macrophages (AM) were examined in 7 nonsmoking healthy control subjects, and 20 smoking patients with chronic obstructive pulmonary diseases (COPD). All patients and subjects were no more than 40 years old. According to the 95% confidence limits of HA and FN in BALF from nonsmoking healthy control subjects, the smoking patients were divided into two groups, those who had HA and FN levels within the limits for nonsmoking controls were classified as the first group (group 1) and those with levels above the control limits were classified as the second group (group 2). Our data showed that the concentrations of HA and FN in BALF and FN released by AM were significantly higher in group 2 than in group 1 patients. There were also significant differences between the two groups in pulmonary function measurements (DLco, FEV1, and FEV1/FVC) which were lower in group 2. HA levels in group 2 patients correlated directly with counts of inflammatory cells in BALF (BALF cells/ml, and numbers/ml of total cells, macrophages, neutrophils and lymphocytes), and the concentration of FN released by AM, and showed an inverse correlation with pulmonary function (DLco and FEV1/FVC). Our results suggest that the inflammatory repair response and fibrosis may play a role in the development of emphysema in young patients with COPD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7569331     DOI: 10.1159/000196406

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  6 in total

Review 1.  Threat matrix: low-molecular-weight hyaluronan (HA) as a danger signal.

Authors:  Jonathan D Powell; Maureen R Horton
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  Enhanced levels of hyaluronan in lungs of patients with COPD: relationship with lung function and local inflammation.

Authors:  M A Dentener; J H J Vernooy; S Hendriks; E F M Wouters
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

Review 3.  Hyaluronan as an immune regulator in human diseases.

Authors:  Dianhua Jiang; Jiurong Liang; Paul W Noble
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

4.  Differences in local versus systemic TNFalpha production in COPD: inhibitory effect of hyaluronan on LPS induced blood cell TNFalpha release.

Authors:  M A Dentener; R Louis; R H E Cloots; M Henket; E F M Wouters
Journal:  Thorax       Date:  2006-03-03       Impact factor: 9.139

Review 5.  The role of hyaluronan synthesis and degradation in the critical respiratory illness COVID-19.

Authors:  Nansy Albtoush; Aaron C Petrey
Journal:  Am J Physiol Cell Physiol       Date:  2022-04-20       Impact factor: 5.282

Review 6.  The Rise and Fall of Hyaluronan in Respiratory Diseases.

Authors:  Mark E Lauer; Raed A Dweik; Stavros Garantziotis; Mark A Aronica
Journal:  Int J Cell Biol       Date:  2015-09-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.